AttendMe Owl Logo
AttendMe
Evidence Evolution
PathologyPathology

How This Evidence Evolved

Liquid Biopsy Maturation

From circulating tumor DNA concept to minimal residual disease detection and multi-cancer screening

15.4

Timeline

Nat Med 2008
2008
Advanced NSCLC plasma profiling
2020
CIRCULATE-Japan
2021
CCGA validation
2021
NILE clinical outcomes
2022
DYNAMIC
2022
NHS-Galleri
2022
ESMO Precision Medicine Working Group ctDNA recommendations
2022
ESMO Precision Medicine Working Group
2022
DYNAMIC-III
2025
Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

A 2008 study measured circulating tumor DNA (ctDNA) in 162 plasma samples from 18 patients undergoing multimodality colorectal-cancer treatment. Tumor-specific mutant fragments were scarce compared with normal circulating DNA, creating a detection and quantification challenge. A highly sensitive personalized approach monitored tumor dynamics during surgery or chemotherapy. This proof of concept supported serial plasma measurement as a way to follow disease, while leaving validation and treatment-guidance questions separate. It did not establish the history of all cell-free-DNA discoveries or a universal benefit from replacing tissue biopsy.
Proof

Landmark RCTs and pivotal trials that established the evidence base

Plasma genomic profiling can identify actionable alterations in advanced NSCLC. In a series of 8,388 patients, somatic alterations were detected in 86% and actionable oncogene alterations in 48%. A later NILE analysis enrolled 282 previously untreated patients with advanced nonsquamous NSCLC: actionable biomarkers were detected by tissue in 21.3% and by cell-free DNA in 27.3%. Time to treatment was shorter when informed by plasma testing than tissue genotyping (18 versus 31 days; P=0.0008). The study supports complementary plasma profiling while separating biomarker detection from regulatory approval claims.
Extension

Follow-up studies, subgroup analyses, and real-world validation

DYNAMIC randomized 455 patients with stage II colon cancer to ctDNA-guided or standard management. Chemotherapy use was 15% versus 28%. Two-year recurrence-free survival was noninferior with ctDNA guidance (93.5% versus 92.4%). All ctDNA-positive patients in the guided strategy were assigned chemotherapy, so this design did not isolate its benefit in positive patients. CIRCULATE-Japan was designed to test both treatment de-escalation in ctDNA-negative and escalation in ctDNA-positive colorectal cancer. Separately, NHS-Galleri is a randomized screening trial designed to measure the incidence of stage III and IV cancer rather than simply the number of cancers detected.
Guidelines

Integration into clinical practice guidelines and recommendations

ESMO’s 2022 report permits validated, sufficiently sensitive ctDNA assays for actionable mutations in advanced cancer, while preferring tissue in many patients and advising reflex tissue testing after noninformative plasma results. Plasma testing may be used when faster results matter or tissue biopsy is impossible or inappropriate. In early-stage cancer, MRD detection can anticipate relapse, but routine MRD-directed treatment and asymptomatic cancer screening are not recommended.
ESMO Precision Medicine Working Group ctDNA recommendations

Validated sensitive ctDNA assays can guide advanced-cancer therapy, subject to assay limits; tissue is preferred for many. MRD-directed treatment is not recommended routinely.

Now

Current standard of care and ongoing research directions

Clinical utility depends on the setting. DYNAMIC supports ctDNA-guided management in stage II colon cancer. DYNAMIC-III studied stage III disease: ctDNA-negative treatment de-escalation reduced oxaliplatin use but did not meet recurrence-free survival noninferiority; escalation did not improve 2-year recurrence-free survival in ctDNA-positive patients. Prognostic information is distinct from benefit from changing treatment. NHS-Galleri was designed to test stage III/IV incidence. The CCGA validation study instead measured sensitivity, specificity and cancer-signal-origin accuracy using a case-controlled observational validation set.

Landmark Trials in This Story

Nat Med 2008Landmark

Circulating mutant DNA to assess tumor dynamics

ctDNA measurement to monitor tumor dynamics during colorectal-cancer therapy

Nat MedTranslational cohortN=18
NILE clinical outcomes2022

Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.

Biomarker detection and clinical outcomes

Clinical lung cancerProspective observational studyN=282
Advanced NSCLC plasma profiling2020

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.

Driver/resistance mutation distribution and frequency

CancerConsecutive plasma profiling cohortN=8,388
DYNAMIC2022Landmark

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

Recurrence-free survival (non-inferiority of ctDNA-guided approach)

New England journal of medicineRCTN=455
NHS-Galleri2022

Cell-Free DNA-Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial.

Stage III/IV cancer incidence at 3–4 years

CancersRandomized screening trial design
CIRCULATE-Japan2021

CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.

ctDNA-guided escalation and de-escalation of adjuvant therapy

Cancer scienceAdaptive platform trial design
DYNAMIC-III2025

Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial.

Recurrence-free survival at three years for ctDNA-negative and two years for ctDNA-positive patients

Nature medicineRandomized phase 2/3 trialN=968
CCGA validation2021

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.

Cancer signal sensitivity, specificity and origin prediction accuracy

Annals of oncology : official journal of the European Society for Medical OncologyProspective case-controlled validation studyN=4,077

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Frequently Asked Questions

What is the difference between liquid biopsy for genotyping and MRD detection?+
Genotyping assays seek actionable mutations to guide advanced-cancer treatment. NILE used Guardant360 plasma profiling in advanced nonsquamous NSCLC. MRD detection instead asks whether ctDNA after early-stage cancer treatment predicts future relapse. ESMO’s 2022 report found strong clinical validity for that prognostic role, while withholding a routine treatment-guidance recommendation because clinical utility was unproven. The assays’ purpose and evidentiary requirements differ.
How does the Galleri multi-cancer screening test work?+
The CCGA validation study used cell-free DNA methylation sequencing and machine learning to detect cancer signals and predict their origin. In 4,077 participants, specificity was 99.5% and overall sensitivity 51.5%. Sensitivity increased from 16.8% in stage I to 90.1% in stage IV. Signals were detected across more than 50 cancer types; origin prediction was correct in 88.7% of true positives.
Can liquid biopsy replace tissue biopsy entirely?+
ESMO recommends validated, sufficiently sensitive ctDNA assays to identify actionable mutations in advanced cancer, while recognizing limitations. Tissue testing remains preferred for many patients because plasma assays can miss fusions and copy-number changes. Plasma testing can be used when speed matters or tissue biopsy is impossible or inappropriate. After a non-informative plasma result, reflex tumor testing should be considered because false negatives occur.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026